Extended Data Fig. 1: Recurrence-free survival outcomes in mouse CLEVER preclinical study following chronic treatment with study agents.
From: Targeting dormant tumor cells to prevent recurrent breast cancer: a randomized phase 2 trial
a, Schematic of orthotopic inducible Her2 mouse model and timing of rapamycin treatment in mice bearing dormant residual tumor cells. b, Recurrence-free survival of female nu/nu mice harboring dormant residual disease from fully regressed primary tumors treated with vehicle control (VEH) or 4 mg/kg RAPA (n = 20) initiated 28 d after Her2 downregulation. c–f, RFS outcomes for mice treated chronically with VEH, RAPA, EVE, CQ, HCQ or EVE + HCQ. c, RAPA or CQ compared to vehicle control (VEH); d, EVE or HCQ compared to VEH; e, RAPA or EVE compared to VEH; or f, HCQ or CQ compared to VEH. RFS outcomes shown in panels c–f and in Fig. 1 represent a single study with 16 treatment arms, where the results for different comparisons between treatment arms and treatment durations are shown as individual panels for clarity. Hazard ratios (HR) and unadjusted p values from the two-sided log-rank test are shown for the indicated comparisons.
